Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 165
Filter
1.
Lupus Sci Med ; 11(1)2024 Feb 07.
Article in English | MEDLINE | ID: mdl-38325898

ABSTRACT

BACKGROUND: Circulating, extracellular RNA is the primary trigger of type I interferon in systemic lupus erythematosus (SLE), and interferon is known to play a central pathogenic role in the disease. RSLV-132 is a catalytically active human RNase molecule fused to human IgG1 Fc designed to digest RNA and thereby decrease the chronic inflammation associated with SLE. The drug was evaluated in a cohort of patients with SLE with moderate-severe cutaneous disease activity and the presence of RNA immune complexes. The primary objective of the study was the assessment of the impact of 13 doses of 10 mg/kg RSLV-132 over 6 months on the mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score. METHODS: Sixty-five patients meeting the entry criteria of a baseline CLASI score of 10 or greater and positivity of at least one of five autoantibodies to RNA-binding proteins (SM/RNP, SSA/Ro, SSB/La, Sm, RNP) were randomly assigned (2:1) to receive 13 doses of RSLV-132 10 mg/kg or placebo, respectively. Participants received study drug for 24 weeks on days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141 and 155 with an end-of-treatment visit on day 169 and a follow-up visit at the end of the study on day 215. The primary objective was assessed on days 85 and 169. Secondary objectives included assessment of systemic disease activity using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), the British Isles Lupus Assessment Group 2004 Index and the Physician's Global Assessment. Data from these instruments were used to calculate the SLE Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) scores. RESULTS: The mean CLASI score change from baseline at day 169 was -5.7 (±7.0) in the placebo group and -6.2 (±8.5) in the RSLV-132 group. A subgroup of participants with moderate-severe systemic disease activity and high baseline SLEDAI scores (≥9) were analysed with respect to BICLA and SRI-4 responses. The RSLV-132 treated participants in the high SLEDAI subgroup had a greater percentage of BICLA responses (62% vs 44%) and SRI-4 responses (23% vs 11%) as compared with placebo. A second subgroup of participants with high baseline CLASI scores (≥21) were analysed with respect to BICLA and SRI-4 responses. The RSLV-132 treated participants in the high CLASI subgroup had a greater percentage of BICLA responses (28% vs 8%) and SRI-4 responses (39% vs 8%) as compared with placebo. CONCLUSIONS: Six months of RSLV-132 therapy consisting of a weekly loading dose of RSLV-132 for 1 month, followed by 5 months of biweekly administrations did not significantly improve the mean CLASI score relative to placebo in this cohort of patients with SLE. The study entry criteria selected patients with moderate-severe cutaneous disease activity and no minimum SLEDAI score, which resulted in a wide range of systemic disease activity from inactive to severe as measured by SLEDAI. When the participants with higher SLEDAI and CLASI scores were analysed, a trend towards clinical improvement favouring RSLV-132 was observed. The results warrant further evaluation of RSLV-132 in SLE and suggest that patients with more active systemic disease are most likely to benefit from RNase therapy.


Subject(s)
Lupus Erythematosus, Discoid , Lupus Erythematosus, Systemic , Recombinant Fusion Proteins , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Treatment Outcome , Ribonucleases/therapeutic use , Immunoglobulin G/therapeutic use , Lupus Erythematosus, Discoid/chemically induced , Lupus Erythematosus, Discoid/drug therapy , RNA/therapeutic use
2.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi ; 34(6): 566-579, 2023 Jan 05.
Article in Chinese | MEDLINE | ID: mdl-36642896

ABSTRACT

OBJECTIVE: To investigate the effect of recombinant Schistosoma japonicum egg ribonuclease SjCP1412 (rSjCP1412) on proliferation, cell cycle, apoptosis and activation of human hepatic stellate cells LX-2 in vitro, and explore the underlying mechanisms. METHODS: The rSjCP1412 protein was expressed in Escherichia coli BL21 by prokaryotic expression, and the highly purified soluble rSjCP1412 protein was prepared by Ni NTA affinity chromatography and urea gradient refolding dialysis. Yeast RNA was digested using 12.5, 25.0, 50.0 µg rSjCP1412 proteins at 37 °C for 2, 3, 4 h, and the enzymatic products were electrophoresed on 1.5% agarose gel to observe the RNAase activity of rSjCP1412 protein. The proliferation of LX-2 cells stimulated by different doses of rSjCP1412 protein for 48 hours was measured using CCK-8 assay, and the apoptosis of LX-2 cells stimulated by different doses of rSjCP1412 protein for 48 hours was detected using the Annexin V-FITC/PI double staining, while the percentage of LX-2 cells at G0/G1, S and G2/M phases of cell cycle following stimulation with different doses of rSjCP1412 protein for 48 h was detected by DAPI staining. The type I collagen, type III collagen and α-smooth muscle actin (α-SMA) mRNA expression was quantified using quantitative florescent real-time PCR (qPCR) assay and Western blotting at transcriptional and translational levels in LX-2 cells following stimulation with different doses of rSjCP1412 protein for 48 h, while soluble egg antigen (SEA) served a positive control and PBS without rSjCP1412 protein as a normal control in the above experiments. The expression of collagen I, α-SMA and Smad4 protein was determined using Western blotting in LX-2 cells following stimulation with rSjCP1412 protein, transforming growth factor-ß1 (TGF-ß1) alone or in combination, to examine the signaling for the effect of rSjCP1412 protein on LX-2 cells. RESULTS: The rSjCP1412 protein was successfully expressed and the highly purified soluble rSjCP1412 protein was prepared, which had a RNase activity. Compared with the normal group, the survival rates of LX-2 cells significantly decreased post-treatment with 12.5, 25.0, 50.0 µg/mL rSjCP1412 protein and SEA for 48 h (F = 22.417 and 20.448, both P values < 0.05). The apoptotic rates of LX-2 cells significantly increased post-treatment with 12.5, 25.0, 50.0 µg/mL rSjCP1412 protein for 48 h (F = 11.350, P < 0.05), and treatment with 12.5, 25.0, 50.0 µg/mL rSjCP1412 protein for 48 h resulted in arrest of LX-2 cells in G0/G1 phase (F = 20.710, P < 0.05). Treatment with 12.5, 25.0, 50.0 µg/mL rSjCP1412 protein for 48 h caused a significant reduction in relative expression levels of collagen I (F = 11.340, P < 0.05), collagen III (F = 456.600, P < 0.05) and α-SMA mRNA (F = 23.100, P < 0.05) in LX-2 cells, and both rSjCP1412 protein and SEA treatment caused a significant reduction in collagen I (F = 1 302.000, P < 0.05), α-SMA (F = 49.750, P < 0.05) and Smad4 protein expression (F = 52.420, P < 0.05) in LX-2 cells. In addition, rSjCP1412 protein treatment inhibited collagen I (F = 66.290, P < 0.05), α-SMA (F = 31.300, P < 0.05) and Smad4 protein expression (F = 27.010, P < 0.05) in LX-2 cells activated by TGF-ß1. CONCLUSIONS: rSjCP1412 protein may induce apoptosis of LX-2 cells and inhibit proliferation, cell cycle and activation of LX-2 cells through down-regulating Smad4 signaling molecules.


Subject(s)
Schistosoma japonicum , Animals , Humans , Schistosoma japonicum/metabolism , Transforming Growth Factor beta1/metabolism , Smad4 Protein/metabolism , Liver Cirrhosis/drug therapy , Hepatic Stellate Cells/pathology , Ribonucleases/metabolism , Ribonucleases/pharmacology , Ribonucleases/therapeutic use , Cell Line , RNA, Messenger/metabolism
3.
Glycoconj J ; 39(2): 157-165, 2022 04.
Article in English | MEDLINE | ID: mdl-35066741

ABSTRACT

Sialic-acid binding lectin from bullfrog (Rana catesbeiana) eggs, cSBL, is a cytotoxic ribonuclease (RNase) belonging to the RNase A superfamily. cSBL is cytotoxic to tumor cells, such as malignant pleural mesothelioma by inducing apoptotic cell death caused by the degradation of RNA in tumor cells. In addition, we have reported some data that cSBL could be involved in the endoplasmic reticulum stress pathway, and it was also assumed to cause apoptotic cell death. The most significant property of cSBL is its specificity toward malignant cells. Furthermore, since the antitumor activity of cSBL was confirmed by in vivo experiments using mouse xenograft models, it is expected to be a candidate for clinical chemotherapy. Here, we summarize the history of cSBL, alternatively called "leczyme," with its present and future.


Subject(s)
Antineoplastic Agents , Apoptosis , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Humans , Lectins/metabolism , Mice , Rana catesbeiana/metabolism , Ribonucleases/metabolism , Ribonucleases/pharmacology , Ribonucleases/therapeutic use
4.
Arthritis Rheumatol ; 73(1): 143-150, 2021 01.
Article in English | MEDLINE | ID: mdl-32798283

ABSTRACT

OBJECTIVE: To assess the safety and efficacy of RSLV-132, an RNase Fc fusion protein, in a phase II randomized, double-blind, placebo-controlled clinical trial in patients with primary Sjögren's syndrome (SS). METHODS: Thirty patients with primary SS were randomized to receive treatment with RSLV-132 or placebo intravenously once per week for 2 weeks, and then every 2 weeks for 12 weeks. Eight patients received placebo and 20 patients received RSLV-132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST). RESULTS: Patients randomized to receive RSLV-132 experienced clinically meaningful improvements in the ESSPRI score (P = 0.27), FACIT-F score (P = 0.05), ProF score (P = 0.07), and DSST (P = 0.02) from baseline to day 99, whereas patients who received placebo showed no changes in any of these clinical efficacy measures. This improvement was significantly correlated with increased expression of selected interferon-inducible genes (Pearson's correlations, each P < 0.05). CONCLUSION: Administration of RSLV-132 improved severe fatigue, as determined by 4 independent patient-reported measures of fatigue, in patients with primary SS.


Subject(s)
Fatigue/physiopathology , Immunoglobulin G/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Ribonucleases/therapeutic use , Sjogren's Syndrome/drug therapy , Adult , Aged , Double-Blind Method , Female , Gene Expression , Humans , Interferons/genetics , Interferons/immunology , Mental Fatigue/physiopathology , Middle Aged , Patient Reported Outcome Measures , Sjogren's Syndrome/genetics , Sjogren's Syndrome/immunology , Sjogren's Syndrome/physiopathology , Treatment Outcome
5.
Virus Res ; 286: 198086, 2020 09.
Article in English | MEDLINE | ID: mdl-32629086

ABSTRACT

Reoviruses (respiratory enteric orphan viruses) are nonenveloped viruses with segmented dsRNA genome. Viruses in the family Reoviridae are quite stable in the environment. Recently, they have been identified with various pathologies and physiologic dysfunctions in a wide range of organs and tissues, including the hepatobiliary system, the myocardium, lungs, and endocrine tissues. Although most cases of reovirus infection are mild or subclinical diseases, the prevention measures are currently needed, especially for young children suffering from dehydrating gastroenteritis. To inhibit viral replication, different RNases targeting viral RNA are proposed. Here, we first have shown that RNase from Bacillus pumilus (binase) acts as an antiviral agent at the level of the whole animal organism infected by Mammalian orthoreovirus 1 strain Lang (TL1). The results obtained on the mice model infected with 10 LD50 and 20 LD50 doses of reovirus indicate the restoration of mice physiological parameters under binase treatment at the dose of 50 µg/mouse. Thus, our research supports the relevance of binase as a promising antiviral agent that affects viral RNA.


Subject(s)
Antiviral Agents/therapeutic use , Lung/drug effects , Orthoreovirus, Mammalian/drug effects , Reoviridae Infections/drug therapy , Ribonucleases/therapeutic use , Animals , Animals, Newborn , Lung/virology , Mice , Mice, Inbred BALB C , Reoviridae Infections/virology , Serogroup , Virus Replication/drug effects
6.
Int Immunopharmacol ; 85: 106608, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32447222

ABSTRACT

The present study was aimed to reveal the function of extracellular RNAs (exRNAs) in retinal ischemia reperfusion (I/R) injury, and evaluate whether RNase administration can effectivelyreduce I/Rinjury. A retinal I/R injury C57BL/6J wild-type mice model was established by elevating intraocular pressure for 1 h. All mice received 3 doses of RNase or the same dose of normal saline at different time points. After 7 days of reperfusion, retinal damage was quantified by counting retinal ganglion cells and measuring retinal layer thickness. The apoptotic retinal cells were detected by the TUNEL experiment, and the expressions of caspase-3, proinflammatory cytokines in retinal tissues, and glial fibrillary acidic protein (GFAP) protein and mRNA were detected to determine the underlying mechanism. It was found that RNase administration (1) reduced the significant loss of retinal morphology caused by I/R injury; (2) down-regulated the expression of NF-κBp65, IL-6 and GFAP relative to the I/R mice; (3) decreased the apoptosis of retinal cells and the levels of caspase-3; (4) attenuated exRNAs levels in retinal tissues on day 7 after retinal I/R. In short, increased exRNAs may contribute to retinal I/R damages in mice, and RNase therapy can effectively attenuate retinal damage by reducing inflammatory response and apoptosis.


Subject(s)
Apoptosis/drug effects , Neuroprotective Agents/pharmacology , Reperfusion Injury/drug therapy , Retina/injuries , Ribonucleases/pharmacology , Animals , Extracellular Vesicles/metabolism , Glial Fibrillary Acidic Protein/metabolism , Inflammation/drug therapy , Interleukin-6/metabolism , Male , Mice, Inbred C57BL , Neuroprotective Agents/therapeutic use , RNA/blood , RNA/genetics , RNA/metabolism , Reperfusion Injury/metabolism , Retina/drug effects , Retina/metabolism , Retina/pathology , Retinal Neurons/drug effects , Ribonucleases/therapeutic use , Transcription Factor RelA/metabolism , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
7.
Int Immunopharmacol ; 83: 106430, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32279043

ABSTRACT

Ribonuclease (RNase) reportedly exerts organ-protective effects in several pathological conditions, including ischemia reperfusion (I/R), but whether it can exhibit protective effect on intestinal I/R injury and potential mechanisms remain unknown. The present study was aimed to evaluate the effects of RNase on intestinal I/R injury and explore the underlying mechanisms. Thirty-two wild-type C57BL/6J adult male mice were evenly divided into a sham group, a sham + RNase group, an I/R group and an I/R + RNase group. Intestinal I/R was produced by clamping the superior mesenteric artery for 1 h followed by reperfusion for 2 h. All mice were treated with 3 doses of RNase or the same dosage of normal saline at different points. It was found that intestinal I/R caused significant intestinal injury and an increase in levels of extracellular RNAs (exRNAs). Treatment with RNase significantly reduced the inflammatory cytokine production, inhibited intestinal apoptosis and down-regulated the expression of toll like receptor 3 in intestinal tissues. In conclusion, increased exRNAs may contribute to intestinal I/R injury in adult mice, and RNase treatment during perioperative window is effective for attenuating intestinal I/R injury.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Intestinal Diseases/drug therapy , Intestines/drug effects , Intestines/injuries , Reperfusion Injury/drug therapy , Ribonucleases/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Apoptosis/drug effects , Cytokines/drug effects , Cytokines/metabolism , Disease Models, Animal , Inflammation/drug therapy , Inflammation/metabolism , Intestinal Diseases/etiology , Intestinal Diseases/metabolism , Intestines/blood supply , Intestines/pathology , Male , Mice , Mice, Inbred C57BL , NF-KappaB Inhibitor alpha/drug effects , NF-KappaB Inhibitor alpha/metabolism , NF-kappa B/drug effects , NF-kappa B/metabolism , RNA/metabolism , Reperfusion Injury/complications , Ribonucleases/therapeutic use , Survival Rate , Toll-Like Receptor 3/metabolism
8.
Biochem Pharmacol ; 167: 173-181, 2019 09.
Article in English | MEDLINE | ID: mdl-31185226

ABSTRACT

Human malignant melanoma is one of the most aggressive cancers, accompanied with poor prognosis, metastatic evolution and high mortality. Many strategies have been developed using BRAF and MEK inhibitors in spite of the classic therapy with alkylating agents, but failure related to the ability of the tumor to activate alternative proliferation pathways occurred after promising initial successes. Poly(ADP-ribose) polymerase (PARP) enzymes are well known to be crucial for DNA damage response, and PARP inhibition results in the accumulation of DNA strand breaks that induce cell injury. For this reason, PARP-inhibitors (PARPi) have become promising tools to counteract many cancer types. One of the most used by clinicians is olaparib, that, however, showed again cancer resistance in patients. Thus, new generation molecules have been designed mainly to counteract this problem. Among them, we chose to test AZD2461 on the particularly aggressive human melanoma A375 cell line. This drug is a PARPi significantly less prone than olaparib to undergo the P-glycoprotein-mediated efflux mechanism, one of those responsible for resistance, that in turn is the main adversity in melanoma therapy. Then, we analysed AZD2461 also together with the enzyme onconase (ONC) on the same A375 cells, to investigate if the combination of drugs could possibly increase the in vitro antitumor activity. ONC is a small amphibian "pancreatic-type" ribonuclease that is able to exert a remarkable antitumor activity against many cancers, either in vitro or in vivo, principally because it can evade the ubiquitous ribonuclease cytosolic inhibitor thanks to its structural determinants. Hence, ONC became relevant in the use of protein-drug strategies against incurable cancers. The studies performed in this work showed that both drugs definitely affect A375 cells viability by inducing cytostatic and pro-apoptotic effects in a time- and dose-dependent manner, either if administered alone or in combination. Although we registered low synergistic effects with the combination of the two drugs, we found that AZD2461 did not induce resistance in A375 after two months treatment with high concentration of this molecule. Moreover, we underline that A375 cells treated for a prolonged time with AZD2461 were definitely more susceptible than parental A375 cells to the pro-apoptotic action of ONC. Considering also the different inhibitory effects of the two drugs on TNF-α gene expression and NF-κB DNA-binding, the tuning of their combined delivery to the A375 tumor cell line might open a promising scenario for future therapeutic applications devoted to defeat human melanoma.


Subject(s)
Antineoplastic Agents/pharmacology , Melanoma/enzymology , Phthalazines/pharmacology , Piperidines/pharmacology , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Ribonucleases/pharmacology , Skin Neoplasms/enzymology , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/immunology , Humans , Melanoma/drug therapy , Phthalazines/therapeutic use , Piperidines/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use , Ribonucleases/therapeutic use , Skin Neoplasms/drug therapy , Melanoma, Cutaneous Malignant
9.
J Allergy Clin Immunol Pract ; 7(5): 1394-1403, 2019.
Article in English | MEDLINE | ID: mdl-31076057

ABSTRACT

Mechanistic studies have improved our understanding of molecular and cellular components involved in asthma and our ability to treat severe patients. An mAb directed against IgE (omalizumab) has become an established add-on therapy for patients with uncontrolled allergic asthma and mAbs specific for IL-5 (reslizumab, mepolizumab), IL-5R (benralizumab), and IL-4R (dupilumab) have been approved as add-on treatments for uncontrolled eosinophilic (type 2) asthma. While these medications have proven highly effective, some patients with severe allergic and/or eosinophilic asthma, as well as most patients with severe non-type-2 disease, have poorly controlled disease. Agents that have recently been evaluated in clinical trials include an antibody directed against thymic stromal lymphopoietin, small molecule antagonists to the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) and the receptor for stem cell factor on mast cells (KIT), and a DNA enzyme directed at GATA3. Antibodies to IL-33 and its receptor, ST2, are being evaluated in ongoing clinical studies. In addition, a number of antagonists directed against other potential targets are under consideration for future trials, including IL-25, IL-6, TNF-like ligand 1A, CD6, and activated cell adhesion molecule (ALCAM). Clinical data from ongoing and future trials will be important in determining whether these new medications will offer benefits in place of or in addition to existing therapies for asthma.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Activated-Leukocyte Cell Adhesion Molecule/immunology , Antibodies, Monoclonal, Humanized/therapeutic use , Antigens, CD/immunology , Antigens, Differentiation, T-Lymphocyte/immunology , Asthma/immunology , Asthma/physiopathology , Cytokines/antagonists & inhibitors , Cytokines/immunology , DNA, Catalytic/therapeutic use , Eosinophils/immunology , GATA3 Transcription Factor , Humans , Imatinib Mesylate/therapeutic use , Indoleacetic Acids/therapeutic use , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Interleukin-6/immunology , Lymphocytes/immunology , Mast Cells/immunology , Molecular Targeted Therapy , Omalizumab/therapeutic use , Proto-Oncogene Proteins c-kit/antagonists & inhibitors , Proto-Oncogene Proteins c-kit/immunology , Pyridines/therapeutic use , Receptors, Immunologic/antagonists & inhibitors , Receptors, Immunologic/immunology , Receptors, Interleukin-17/antagonists & inhibitors , Receptors, Interleukin-17/immunology , Receptors, Prostaglandin/antagonists & inhibitors , Receptors, Prostaglandin/immunology , Ribonucleases/therapeutic use , Th2 Cells/immunology , Tumor Necrosis Factor Ligand Superfamily Member 15/antagonists & inhibitors , Tumor Necrosis Factor Ligand Superfamily Member 15/immunology
10.
Dev Comp Immunol ; 91: 8-16, 2019 02.
Article in English | MEDLINE | ID: mdl-30267738

ABSTRACT

RNase1 is an enzyme important in host defense in vertebrates where it degrades the RNA of bacteria and viruses. We evaluated the effect of RNase1 on the resistance to Aeromonas hydrophila infection in Megalobrama amblycephala. The fish were randomly divided into four groups: a blank group (none-treated M. amblycephala), a control group (injected PBS), a challenge group (A. hydrophila-injected) and a treatment group (pre-treated with RNase1 24 h before the A. hydrophila injection), and we collected five tissues of each group. Then we recorded changes in the levels of glutathione (GSH), oxidized glutathione (GSSG), hepatic catalase (CAT), superoxide dismutase (SOD), malondialdehyde (MDA) and lysozyme; and the relative mRNA expression of catalase (CAT), selenium-dependent glutathione peroxidase (GPx), Cu/Superoxide dismutase (Cu/Zn-SOD), glutamate-cysteine ligase (GCLC), glutathione reductase (GR) and nuclear factor erythroid 2-related factor 2 (Nrf2) for four groups. The expression of six genes was highest in liver and blood of the blank group. It was significantly higher in the gut of the treatment group (compared to control and challenge groups) 12 h after the infection. The treatment group exhibited a significant increase in GSH, SOD and CAT activity, and a decrease in GSSG, MDA and lysozyme content (compared to the control and challenge groups) 6 and 12 h after infection. These results suggest that supplementation with RNase1 protein can enhance resistance against A. hydrophila infections in M. amblycephala.


Subject(s)
Aeromonas hydrophila/immunology , Cyprinidae/immunology , Fish Diseases/therapy , Gram-Negative Bacterial Infections/drug therapy , Ribonucleases/therapeutic use , Animals , Catalase/metabolism , Dietary Supplements , Fish Diseases/immunology , Fish Proteins/metabolism , Glutathione/metabolism , Gram-Negative Bacterial Infections/immunology , Immunity, Innate , Superoxide Dismutase/metabolism
11.
J Exp Ther Oncol ; 12(2): 113-120, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29161778

ABSTRACT

INTRODUCTION: Photochemical Internalization is a novel drug delivery technology for cancer treatment based on the principle of Photodynamic Treatment. Using a photosensitizer that locates in endocytic vesicles membranes of tumor cells, Photochemical internalization enables cytosolic release of endocytosed antitumor agents in a site-specific manner. The purpose of the present in-vitro study was to explore whether Photochemical Internalization is able to enhance the efficacy of Ranpirnase, a cytotoxic amphibian ribonuclease, for eradication of squamous cell carcinoma of the head and neck. METHODS: Cell viability was measured in 8 primary human cell lines of squamous cell carcinoma of the head and neck after treatment with Ranpirnase and Photochemical Internalization. For Photochemical Internalization the photosensitizer disulfonated tetraphenyl porphine was incubated with tumor cells followed by exposure to blue light (435 nm). RESULTS: Our study demonstrates significant enhancement of antitumor activity of Ranpirnase by Photochemical Internalization. Treatment responses were heterogeneous between the primary cancer cell lines. Combining Photochemical Internalization with Ranpirnase resulted in 4.6 to 1,940-fold increased cytotoxicity when compared with the ribonuclease alone (P < 0.05). CONCLUSION: Cytotoxicity of Ranpirnase can be markedly enhanced by Photochemical Internalization in squamous cell carcinoma of the head and neck.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Photochemotherapy/methods , Ribonucleases/therapeutic use , Cell Line, Tumor , Drug Delivery Systems , Humans , Photochemistry , Squamous Cell Carcinoma of Head and Neck
12.
Int Rev Immunol ; 36(4): 207-219, 2017 07 04.
Article in English | MEDLINE | ID: mdl-28282218

ABSTRACT

Immunotoxins are a novel class of cancer therapeutics that contains a cytotoxic agent fused to a targeting moiety. Various toxic agents from different sources are used in immunotoxin development, including bacterial, plant and human origin cytotoxic elements. Although bacterial and plant-derived toxins are highly toxic and commonly used in immunotoxins, their immunogenicity for human restricted their application in cancer therapy. Here, we discuss the advantages and limitations of bacterial toxins such as Pseudomonas and Diphtheria toxins, plant toxins such as ricin and gelonin, and some endogenous protein of human origin such as RNases and Granzymes. This article will also review different generations of immunotoxins with special focus on immunotoxins which are under clinical trials or approved for clinical use. Finally, current deimmunization strategies for development of new less-immunogenic recombinant immunotoxins will be discussed. ABBREVIATIONS: mAbs: Monoclonal antibodies; EF2: elongation factor 2; ITs: Immunotoxins; DT: Diphtheria toxin; PE: Pseudomonas exotoxin; dgA: de-glycosylated A-chain of ricin; rGel: recombinant de-glycosylated form of gelonin; NKC: natural killer cells; HTR: human transferrin receptor; EGF: epidermal growth factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; DAB389: truncated Diphtheria toxin; B-CCL: B-cell chronic lymphocytic leukemia; RCC: renal cell carcinoma; GVHD: Graft-versus-host disease; EGFR: epidermal growth factor receptor; AML: acute myeloid leukemia; Fab: fragment antigen-binding; dsFv: disulfide-stabilized fragment variable; scFv: single-chain fragment variable; B-ALL: B-lineage Acute Lymphoblastic Leukemia; Fv: fragment variable; HCL: hairy cell leukemia; IL-2R: Interleukin-2 receptor; CR: complete response; CLL: chronic lymphocytic leukemia; ATL: adult T-cell leukemia; DARPins: designed Ankyrin repeat proteins; pmol: picomolar; HAMA: human-anti mouse antibody.


Subject(s)
Antineoplastic Agents/therapeutic use , Immunotherapy/methods , Immunotoxins/therapeutic use , Neoplasms/therapy , Animals , Clinical Trials as Topic , Desensitization, Immunologic , Diphtheria Toxin/therapeutic use , Granzymes/therapeutic use , Humans , Mice , Neoplasms/immunology , Ribonucleases/therapeutic use , Ribosome Inactivating Proteins, Type 1/therapeutic use , Ricin/therapeutic use
13.
Antivir Ther ; 22(3): 247-255, 2017.
Article in English | MEDLINE | ID: mdl-28121292

ABSTRACT

BACKGROUND: Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials. METHODS: As initial verification of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated. RESULTS: In cultured cells, ranpirnase showed specific activity against HPV-11 with low toxicity (selectivity index >88). The broad applicability of ranpirnase for treating papillomaviruses was verified using the cottontail rabbit papillomavirus. In the clinical study, eight participants were lost-to-follow-up or discontinued due to protocol violation or non-compliance. Among 30 evaluable participants, topical ranpirnase was moderately well-tolerated, with discontinuation by 5 (16.7%) due to adverse reactions. Clinical healing was achieved by 25 participants (83.3%) and 50% improvement by the 5 discontinued participants (16.7%). The median time to clinical healing was 30 days. CONCLUSIONS: This study provides the first in vitro and clinical evidence of the antiviral efficacy of ranpirnase against HPV and supports assessment of ranpirnase in expanded clinical studies.


Subject(s)
Condylomata Acuminata/drug therapy , Condylomata Acuminata/virology , Papillomaviridae/drug effects , Papillomavirus Infections/drug therapy , Papillomavirus Infections/virology , Ribonucleases/therapeutic use , Administration, Topical , Adult , Animals , Cell Line , Cells, Cultured , Combined Modality Therapy , Condylomata Acuminata/pathology , Dose-Response Relationship, Drug , Humans , Kappapapillomavirus/drug effects , Kappapapillomavirus/genetics , Male , Mice , Middle Aged , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/pathology , Rabbits , Ribonucleases/pharmacology , Treatment Outcome , Young Adult
14.
Int Immunopharmacol ; 40: 288-293, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27643662

ABSTRACT

Treatment with ribonuclease (RNase) reportedly protects the heart after myocardial ischemia-reperfusion (I/R), but its potential effect on lung I/R injury (LIRI) is unknown. Thus, we aim to explore whether RNase treatment would relieve LIRI. Thirty-six C57BL/6J adult male wild-type mice were evenly divided into I/R+RNase (I/R+R) group, I/R group, and sham group. Lung I/R was induced by left pulmonary hilum occlusion for 1h and reperfusion for 2h. All mice were treated with RNase or same dosage of normal saline in advance. After I/R, blood and lung tissues were collected for analysis. The results showed that lung injury scores, wet/dry ratio, expressions of inflammatory cytokines, pulmonary apoptosis, and levels of serum extracellular RNA (exRNA), including microRNAs, were markedly elevated after I/R. However, RNase treatment significantly attenuated cytokine production in both lung tissue and serum and also suppressed pulmonary apoptosis as reflected by TUNEL staining and activated caspase-3. In addition, total serum exRNA levels in the I/R+R group had a downward trend versus the I/R group. In conclusion, the increase of circulating exRNA levels contributed to LIRI in adult mice, which could be relieved by injection of RNase during perioperative window. The potential mechanism is the decrease of serum exRNA level and the suppression of pulmonary inflammation and apoptosis.


Subject(s)
Acute Lung Injury/drug therapy , RNA/blood , Reperfusion Injury/drug therapy , Ribonucleases/therapeutic use , Acute Lung Injury/blood , Acute Lung Injury/etiology , Acute Lung Injury/pathology , Animals , Interleukin-6/blood , Interleukin-6/genetics , Lung/drug effects , Lung/pathology , Male , Mice, Inbred C57BL , NF-kappa B/blood , NF-kappa B/genetics , Reperfusion Injury/blood , Reperfusion Injury/complications , Reperfusion Injury/pathology , Ribonucleases/pharmacology , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/genetics
15.
Exp Oncol ; 38(1): 2-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27031711

ABSTRACT

In the review, the use of the ribonucleases for cancer therapy is discussed. Using of epigenetic mechanisms of regulation--blocking protein synthesis without affecting the DNA structure--is a promising direction in the therapy. The ribonucleases isolated from different sources, despite of similar mechanism of enzymatic reactions, have different biological effects. The use of enzymes isolated from new sources, particularly from plants and fungi, shows promising results. In this article we discuss the new approach for the use of enzymes resistant to inhibitors and ribozymes, that is aimed at the destruction of the oncogene specific mRNA and the induction of apoptosis.


Subject(s)
Neoplasms/therapy , Ribonucleases/therapeutic use , Animals , Fungi/enzymology , Humans , Neoplasms/genetics , Neoplasms/metabolism , Oncogenes , Plants/enzymology , RNA, Messenger/genetics , RNA, Messenger/metabolism
16.
Microrna ; 5(1): 12-18, 2016.
Article in English | MEDLINE | ID: mdl-26817512

ABSTRACT

Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis. To date, there are very few treatment options available and the refractoriness to the majority of therapeutic strategies, leading to consider MPM a relevant problem in public health. Therefore, the identification of novel prognostic markers and alternative therapeutic strategies remain a top priority. Several efforts have been made in this direction and to date a number of studies have investigated the role of microRNA as biomarkers in MPM, identifying the potential prognostic role of miR-29c* and miR-31. Very recently, the first microRNA signature able to discriminate poor or and good prognosis of MPM patients underwent surgery has been published. Very interestingly, several microRNA such as miR-1, miR-16, and miR-34b/c have been identified as potential therapeutic agents. Indeed, the forced expression of these microRNA resulted in anti-tumor effects both in vitro and in vivo. Besides, the introduction of microRNA mimic, some agents such as EphrinA1 and Onconase, seemed to exert anti-tumor effects through specific microRNA. Moreover, microRNA have also been reported to play a role in chemoresistance enhancing the sensitivity to specific drug such as pemetrexed. In this review the most relevant and updated data about the role of microRNA as prognostic markers and therapeutic agents in MPM will be presented, opening new avenues towards improved management of this aggressive disease.


Subject(s)
Biomarkers, Tumor/genetics , Lung Neoplasms/genetics , Mesothelioma/genetics , MicroRNAs/genetics , Pleural Neoplasms/genetics , Antineoplastic Agents/therapeutic use , Ephrins/therapeutic use , Gene Expression Regulation, Neoplastic , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Mesothelioma/drug therapy , Mesothelioma/mortality , Mesothelioma, Malignant , Pemetrexed/therapeutic use , Pleural Neoplasms/drug therapy , Pleural Neoplasms/mortality , Prognosis , Ribonucleases/therapeutic use
19.
N Engl J Med ; 372(21): 1987-95, 2015 May 21.
Article in English | MEDLINE | ID: mdl-25981191

ABSTRACT

BACKGROUND: The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of GATA3, an important transcription factor of the Th2 pathway, may be beneficial. We evaluated the safety and efficacy of SB010, a novel DNA enzyme (DNAzyme) that is able to cleave and inactivate GATA3 messenger RNA (mRNA). METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter clinical trial of SB010 involving patients who had allergic asthma with sputum eosinophilia and who also had biphasic early and late asthmatic responses after laboratory-based allergen provocation. A total of 40 patients could be evaluated; 21 were assigned to receive 10 mg of SB010, and 19 were assigned to receive placebo, with each study drug administered by means of inhalation once daily for 28 days. An allergen challenge was performed before and after the 28-day period. The primary end point was the late asthmatic response as quantified by the change in the area under the curve (AUC) for forced expiratory volume in 1 second (FEV1). RESULTS: After 28 days, SB010 attenuated the mean late asthmatic response by 34%, as compared with the baseline response, according to the AUC for FEV1, whereas placebo was associated with a 1% increase in the AUC for FEV1 (P=0.02). The early asthmatic response with SB010 was attenuated by 11% as measured by the AUC for FEV1, whereas the early response with placebo was increased by 10% (P=0.03). Inhibition of the late asthmatic response by SB010 was associated with attenuation of allergen-induced sputum eosinophilia and with lower levels of tryptase in sputum and lower plasma levels of interleukin-5. Allergen-induced levels of fractional exhaled nitric oxide and airway hyperresponsiveness to methacholine were not affected by either SB010 or placebo. CONCLUSIONS: Treatment with SB010 significantly attenuated both late and early asthmatic responses after allergen provocation in patients with allergic asthma. Biomarker analysis showed an attenuation of Th2-regulated inflammatory responses. (Funded by Sterna Biologicals and the German Federal Ministry of Education and Research; ClinicalTrials.gov number, NCT01743768.).


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , DNA, Catalytic/therapeutic use , GATA3 Transcription Factor/metabolism , RNA, Messenger/metabolism , Ribonucleases/therapeutic use , Administration, Inhalation , Adult , Anti-Asthmatic Agents/adverse effects , Area Under Curve , Asthma/metabolism , Biomarkers/blood , DNA, Catalytic/adverse effects , Double-Blind Method , Forced Expiratory Volume , GATA3 Transcription Factor/genetics , Humans , Interleukin-5/blood , Male , Middle Aged , Phenotype , Ribonucleases/adverse effects , Th2 Cells/metabolism , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...